|
Malignant neoplasm of prostate
|
0.310 |
Biomarker
|
disease |
BEFREE |
Therefore, silencing of HP1β and HP1γ may be a promising therapeutic strategy for treatment of prostate cancer.
|
23536649 |
2013 |
|
Malignant neoplasm of prostate
|
0.310 |
Biomarker
|
disease |
CTD_human |
Global analysis of differentially expressed genes in androgen-independent prostate cancer.
|
17199135 |
2007 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Global analysis of differentially expressed genes in androgen-independent prostate cancer.
|
17199135 |
2007 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
High CBX1 expression was significantly associated with larger tumor size, poor tumor differentiation and tumor vascular invasion.
|
30031230 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Polycomb chromobox (CBX) proteins are involved in gene silencing to function as oncogenes or tumor suppressors through the polycomb repressive complex (PRC1).
|
29229426 |
2018 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The function of each polycomb chromobox (CBX) protein in cancer is cell-type-dependent.
|
28912889 |
2017 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
The function of each polycomb chromobox (CBX) protein in cancer is cell-type-dependent.
|
28912889 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Polycomb chromobox (CBX) proteins participate in the polycomb repressive complex (PRC1) that mediates epigenetic gene silencing and endows PRC1 with distinct oncogenic or tumor suppressor functions in a cell-type-dependent manner.
|
27864346 |
2016 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
57.4-60.1% of samples examined showed high HP1β expression and 39.9-42.6 % of examined tumors showed no or low expression of each HP1 subtype.
|
25769025 |
2015 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The effect of polycomb chromobox (Cbx) proteins in cancer is context-dependent.
|
25360999 |
2014 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Here, we show that HP1β negatively regulates the expression and activation of matrix metallopeptidase (MMP)2, which mediates cancer metastasis by destructing type Ⅳ collagen.
|
25201136 |
2014 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
These results suggest the reduction of HP1β followed by a decrease in HP1α contributes to the pathogenesis of thyroid carcinomas, and their loss is a potential marker of thyroid malignancy and metastatic potential, respectively.
|
24840329 |
2014 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Here, we show that HP1β negatively regulates the expression and activation of matrix metallopeptidase (MMP)2, which mediates cancer metastasis by destructing type Ⅳ collagen.
|
25201136 |
2014 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
The effect of polycomb chromobox (Cbx) proteins in cancer is context-dependent.
|
25360999 |
2014 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
These results suggest the reduction of HP1β followed by a decrease in HP1α contributes to the pathogenesis of thyroid carcinomas, and their loss is a potential marker of thyroid malignancy and metastatic potential, respectively.
|
24840329 |
2014 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis also showed that high mRNA expressions of CBX1/2/3/6/8 were independent prognostic factors for shorter OS of HCC patients.
|
30481161 |
2018 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Patients with elevated expression of CBX1 were frequently accompanied with unfavorable overall and disease-free survivals in two independent cohorts consisting of 648 HCC cases.
|
30031230 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Cbx2, a member of the Cbx protein family, is hypothesized to exhibit a vital role in breast cancer.
|
28454227 |
2017 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Cbx2, a member of the Cbx protein family, is hypothesized to exhibit a vital role in breast cancer.
|
28454227 |
2017 |
|
Mammary Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Noteworthily, CBX1 and CBX2 were associated with chemoresistance whereas CBX7 was associated with tamoxifen sensitivity, as well as chemosensitivity in breast tumors.
|
29190923 |
2017 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining against HP1α, HP1β and HP1γ shows that respective HP1 expression level is frequently altered in breast cancers.
|
25769025 |
2015 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.
|
25769025 |
2015 |
|
Mammary Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
We found that the patient group overexpressing HP1β mRNA is associated with poorly differentiated breast tumors and with a significantly lower survival rate.
|
25769025 |
2015 |
|
Heart failure with preserved ejection fraction [HFpEF]
|
0.010 |
Biomarker
|
disease |
BEFREE |
Seven patients with HFpEF performed three bouts of two exercise transitions: MOD1, rest to 4-min moderate-intensity cycling and MOD2, MOD1 preceded by heavy-intensity cycling.
|
30601707 |
2019 |
|
Drug abuse
|
0.010 |
Biomarker
|
group |
BEFREE |
The received results have indicated that two major IBU metabolites, CBX IBU and 2-OH IBU can be important markers for the IBU abuse in view of doping control in equestrian sports.
|
29453024 |
2018 |